Petefészekrák: nyitott vizsgálatok itt: Japán
48 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Where
- Akashi, Gunma, Kagoshima, Koto-ku, Kure, Minato-ku, Tokyo, Okayama, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Tōon
- Age
- 18 év and over
- People
- 880 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT06580314Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya, Niigata, Osaka, Ota-shi, Sagamihara-shi, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Suita, Sunto-gun, Toon-Shi, Tsu, Yokohama
- Age
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025EU 2026-526895-22-00Regiszter frissítve: 2026-11-06
1/2. fázisToborozTrial-stage medicine
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
- Age
- 18 év and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Where
- Akashi, Gunma, Hiroshima, Koto-ku, Kyoto, Matsuyama, Okayama, Saitama, Sapporo, Showa-Ku Nagoya, Tokyo, Tōon
- Age
- 18 év to 60 év
- People
- 3960 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05879926Regiszter frissítve: 2026-11-04
1. fázisToborozTrial-stage medicine
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Shizuoka, Tokyo
- Age
- 18 év and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472EU 2024-511238-11-00Regiszter frissítve: 2026-11-04
1. fázisToborozTrial-stage medicine
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
- Age
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069EU 2024-512927-36-00Regiszter frissítve: 2026-11-04
2. fázisToborozTrial-stage medicine
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Chuo Ku, Kashiwa, Koto-ku, Nagoya, Sakai, Sapporo
- Age
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819EU 2024-517419-62-00Regiszter frissítve: 2026-11-04
1. fázisToborozTrial-stage medicine
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Chiba, Kyoto
- Age
- 18 év and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791EU 2025-521887-37-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya, Niigata, Okayama, Otashi, Sapporo, Sendai, Shiwa-gun Yahaba-cho, Suita, Tōon, Tsu
- Age
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804EU 2025-522255-25-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Chuo Ku Niigata, Tokushima, Tokyo, Yamagata
- Age
- 18 év and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141EU 2025-524202-15-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
- Where
- Niigata, Osaka
- Age
- 18 év and over
- People
- 720 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07694427EU 2025-523365-13-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Aichi, Miyagi, Osaka, Tokyo, Tsu
- Age
- 18 év and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781EU 2023-508204-38-00Regiszter frissítve: 2026-11-02
3. fázisToborozTrial-stage medicine
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Akashi, Fukushima, Hidaka, Kōtoku, Kurume, Nagoya, Nakatogari, Niigata, Okayama, Osaka, Sapporo, Tokyo, Tsu, Yahaba-cho, Yamagata
- Age
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007EU 2024-516982-35-00Regiszter frissítve: 2026-10-28
2/3. fázisToborozTrial-stage medicine
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-chō, Nagoya, Niigata, Okayama, Osaka, Sapporo, Shiwa-gun
- Age
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025EU 2023-507914-28-00Regiszter frissítve: 2026-10-26
2. fázisToborozTrial-stage medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
- Age
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478EU 2023-507641-29-00Regiszter frissítve: 2026-10-26
1/2. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064EU 2023-509632-26-00Regiszter frissítve: 2026-10-26
1. fázisToborozTrial-stage medicine
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Where
- Tokyo
- Age
- 18 év and over
- People
- 138 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314EU 2025-523232-39-00Regiszter frissítve: 2026-10-20
3. fázisToborozTrial-stage medicine
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Natori-shi, Sagamihara-shi, Shinjuku-ku, Suita-shi, Toyoake-shi, Yokohama
- Age
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666EU 2026-526776-23-00Regiszter frissítve: 2026-10-16
1/2. fázisToborozTrial-stage medicine
SMP-3124LP in Adults With Advanced Solid Tumors
- Where
- Kashiwa-shi, Kyoto
- Age
- 18 év and over
- People
- 120 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT06526819Regiszter frissítve: 2026-10-15
3. fázisToborozTrial-stage medicine
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama, Osaka, Sapporo, Sendai, Shiwa-gun, Shizuoka, Tokyo
- Age
- 18 év and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779EU 2025-522748-42-00Regiszter frissítve: 2026-10-15
3. fázisToborozTrial-stage medicine
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
- Where
- Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama, Tottori
- Age
- 18 év and over
- People
- 450 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07286266EU 2025-523361-25-00Regiszter frissítve: 2026-10-15
1. fázisToborozTrial-stage medicine
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
- Age
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481EU 2023-506227-29-00Regiszter frissítve: 2026-10-14
1/2. fázisToborozTrial-stage medicine
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
- Age
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482EU 2022-502759-70-01Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Fukuoka, Hidaka, Kagoshima, Kashiwa, Koto, Kurume, Matsuyama, Nagoya, Niigata, Osaka, Ōta, Sapporo, Shinjyuku, Shiwa-gun, Sunto-gun,, Tōon
- Age
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467EU 2023-508015-23-00Regiszter frissítve: 2026-10-13
1. fázisToborozTrial-stage medicine
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Where
- Hidaka, Kashiwa-shi, Sunto-gun
- Age
- 18 év and over
- People
- 285 worldwide
- Run by
- AbbVie
See details and how to joinNCT07278336EU 2025-522209-40-00Regiszter frissítve: 2026-10-13
Minden vizsgálat (Petefészekrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.